

www.drugabuse.gov

National Institute on Drug Abuse ● National Institutes of Health ● U.S. Department of Health & Human Services

MDMA (Ecstasy)

MDMA (3-4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug chemically similar to the stimulant methamphetamine and the hallucinogen mescaline. Street names for MDMA include Ecstasy, Adam, XTC, hug, beans, and love drug. In 2003, an estimated 470,000 people in the U.S. age 12 and older used MDMA in the past 30 days, a significant decrease from 2002.*

Research in animals indicates that MDMA is neurotoxic; whether or not this is also true in humans is currently an area of intense investigation. MDMA can also be dangerous to health and, on rare occasions, lethal.

MDMA exerts its primary effects in the brain on neurons that use the chemical serotonin to communicate with other neurons. The serotonin system plays an important role in regulating mood, aggression, sexual activity, sleep, and sensitivity to pain.

Health Hazards -

Cognitive Effects

Chronic users of MDMA perform more poorly than nonusers on certain types of cognitive or memory tasks. Some of these effects may be due to the use of other

drugs in combination with MDMA, among other factors.

Physical Effects

In high doses, MDMA can interfere with the body's ability to regulate temperature. This can lead to a sharp increase in body temperature (hyperthermia), resulting in liver, kidney, and cardiovascular system failure.

Because MDMA can interfere with its own metabolism (breakdown within the body), potentially harmful levels can be reached by repeated drug use within short intervals.

Users of MDMA face many of the same risks as users of other stimulants such as cocaine and amphetamines. These include increases in heart rate and blood pressure, a special risk for people with circulatory problems or heart disease, and other symptoms such as muscle tension, involuntary teeth clenching, nausea, blurred vision, faintness, and chills or sweating.

Psychological Effects

These can include confusion, depression, sleep problems, drug craving, and severe anxiety. These problems can occur during and sometimes days or weeks after taking MDMA.

March 2005 Page 1 of 3

w w w . d r u g a b u s e . g o v

National Institute on Drug Abuse • National Institutes of Health • U.S. Department of Health & Human Services

Neurotoxicity

Research in animals links MDMA exposure to long-term damage to neurons that are involved in mood, thinking, and judgment. A study in nonhuman primates showed that exposure to MDMA for only 4 days caused damage to serotonin nerve terminals that was evident 6 to 7 years later. While similar neurotoxicity has not been definitively shown in humans, the wealth of animal research indicating MDMA's damaging properties suggests that MDMA is not a safe drug for human consumption.

Hidden Risk: Drug Purity

Other drugs chemically similar to MDMA, such as MDA (methylenedioxyamphetamine, the parent drug of MDMA) and PMA (paramethoxyamphetamine, associated with fatalities in the U.S. and Australia) are sometimes sold as ecstasy. These drugs can be neurotoxic or create additional health risks to the user. Also, ecstasy tablets may contain other substances in addition to MDMA, such as ephedrine (a stimulant); dextromethorphan (DXM, a cough suppressant that has PCP-like effects at high doses); ketamine (an anesthetic used mostly by veterinarians that also has PCP-like effects); caffeine; cocaine; and methamphetamine. While the combination of MDMA with one or more of these drugs may be inherently dangerous, users might also combine them with substances such as

marijuana and alcohol, putting themselves at further physical risk.

Extent of Use -

Community Epidemiology Work Group (CEWG)**

CEWG members monitor drug use data sources for 21 metropolitan areas nationwide. In many of these areas monitored by CEWG members, MDMA, once used primarily at dance clubs, raves, and college scenes, is being used in a number of other social settings. In addition, some members reported increased use of MDMA among African-American and Hispanic populations.

The number of MDMA emergency department (ED) mentions decreased in nine CEWG areas from 2001 to 2002, with a significant increase reported only in New Orleans. The highest numbers of MDMA ED mentions in the 2002 period were in Philadelphia, Los Angeles, New York, Miami, San Francisco, Atlanta, Boston, and Detroit.

2004 Monitoring the Future Survey (MTF)***

Tenth-graders showed significant changes in MDMA use and related attitudes from 2003 to 2004. They reported an increase (+3.0 percent) in perceived harmfulness of occasional MDMA use, and lifetime**** use decreased, from 5.4 percent to 4.3

March 2005 Page 2 of 3



www.drugabuse.gov

National Institute on Drug Abuse • National Institutes of Health • U.S. Department of Health & Human Services

percent. In addition, both 10th- and 12thgraders reported significant increases in their disapproval of trying MDMA once or twice over the same period. For more information, please visit www.ClubDrugs.org and www.Teens.drugabuse.gov.

- * NSDUH (formerly known as the National Household Survey on Drug Abuse) is an annual survey of Americans age 12 and older conducted by the Substance Abuse and Mental Health Services Administration. Copies of the latest survey are available at www.samhsa.gov and from the National Clearinghouse for Alcohol and Drug Information at 1-800-729-6686.
- ** CEWG researchers meet twice yearly to share emerging trends in drug abuse for 21 major U.S. metropolitan areas. This report was based on data published in the CEWG Advance Report for December 2003. CEWG reports are on NIDA's Web site at www.drugabuse.gov.
- *** These data are from the 2004 Monitoring the Future Survey, funded by the National Institute on Drug Abuse, National Institutes of Health, DHHS, and conducted by the University of Michigan's Institute for Social Research. The survey has tracked 12th-graders' illicit drug use and related attitudes since 1975; in 1991, 8th- and 10th-graders were added to the study. The latest data are online at www.drugabuse.gov.
- **** "Lifetime" refers to use at least once during a respondent's lifetime. "Annual" refers to an individual's drug use at least once during the year preceding their response to the survey. "30-day" refers to an individual's drug use at least once during the month preceding their response to the survey.



National Institutes of Health - U.S. Department of Health and Human Services

This material may be used or reproduced without permission from NIDA. Citation of the source is appreciated.

March 2005 Page 3 of 3